While organizations have invested heavily in expanding ambulatory networks, many are discovering that operational workflows have not evolved at the same pace. The result is a growing gap between demand and the systems designed to manage it. The post Ambulatory Growth Demands a New Operating Model appeared first on MedCity News.

Revenue cycle vendor Unlimited Technology Systems disclosed a ransomware attack affecting 3.8 million patients — the second-largest healthcare data breach reported to HHS this year. The post Health IT Vendor’s Data Breach Exposes Nearly 4M Patient Records appeared first on MedCity News.

NOCD, a virtual provider for OCD, announced plans to expand its virtual intensive outpatient program for people with severe OCD nationwide. The post NOCD Announces Plans for National Expansion of Intensive Outpatient Therapy appeared first on MedCity News.

Immunology startup Infinimmune is developing antibody drugs with potential advantages over traditional monoclonal antibodies. The Series A financing will support two lead programs entering the clinic in atopic dermatitis. The post Infinimmune Secures $75M for a More Human Approach to Developing Better Antibody Drugs appeared first on MedCity News.

Tolerance for this abrasion is gone. It wastes time, drains staff capacity, drives up costs, and affects the patient experience. The post From Friction to Fix: Measuring What’s Breaking Payer-Provider Trust appeared first on MedCity News.

[Sponsored] A new report from Forrester offers a score card assessing health tech vendors on customer experience for healthcare organizations considering adopting them. The post Which Health Tech Companies Are Getting Customer Experience Right? appeared first on MedCity News.

CMS unveiled new details of its new RAPID pathway, which is designed to close the gap between FDA approval and Medicare coverage for breakthrough medical devices. Industry reaction has been largely positive, as medical device companies often sit in “coverage purgatory” for years. The post How CMS Is Tackling ‘Coverage Purgatory’ for Medical Devices appeared first on MedCity News.

Tanvi Patel, vice president and general manager of Amazon Pharmacy, and her co-panelists at the recent Bullseye event, explained why PBMs, payers and doctors are all hampering consumer choice when it comes to patients getting affordable drugs. The post Amazon Pharmacy Executive: Formularies are Anti-Choice appeared first on MedCity News.

Small group insurers are proposing a median 14% premium increase for 2027, driven by rising healthcare costs. The post Small Businesses Could Face Double-Digit Premium Hikes in 2027 appeared first on MedCity News.

Jazz Pharmaceuticals, maker of the blockbuster epilepsy drug Epidiolex, is acquiring Actio Biosciences and its lead drug in pivotal testing for a rare type of epilepsy with no FDA-approved treatments. It’s Jazz’s second epilepsy deal in the past year. The post Jazz Pharma Expands Again in Epilepsy With $820M Actio Bio Acquisition appeared first on MedCity News.

In this episode of the MedCity Pivot Podcast, CVS Health Aetna’s chief digital and technology officer talks about how the insurance business is using AI, especially agentic AI, in healthcare. Point to note: AI is not used in automatic denials of coverage. The post MedCity Pivot: How Aetna is Adopting Agentic AI appeared first on MedCity News.

Drug development isn’t limited by the amount of data we collect, but by our ability to preserve the context, meaning and relationships that transform data into evidence. The post AI in Drug Development is Not a Data Problem — It’s An Evidence Problem appeared first on MedCity News.

Ascension is pushing AI beyond note-taking to tackle the billing, order entry and nursing handoff work still weighing on clinicians after a patient visit ends. The post How to Keep Clinicians Satisfied, the Ascension Way appeared first on MedCity News.

[Sponsored] With home health fraud growing more sophisticated through AI, post-pay audits are no longer enough. Payers must shift to proactive, tech-driven prevention to catch improper claims before paying them. The post Compliance Alone Won’t Fix the Home Health Fraud Problem appeared first on MedCity News.

In addition to pricing the biggest biotech IPO of the week, Braveheart Bio’s underwriters exercised their option to purchase more shares, boosting the clinical-stage company’s total haul to nearly $440 million. Braveheart’s lead drug could be competitive with a blockbuster Bristol Myers Squibb medicine for a type of cardiomyopathy. The post Braveheart Bio’s $382M IPO for Heart Drug Leads a Big Week for Biotech IPOs appeared first on MedCity News.